[Adverse reactions in metrizamide-meatocisternography (author's transl)].
To avoid disantvantages and possible late reactions of oily contrast medium we performed 18 Meatocisternographies using the watersoluble contrast medium Metrizamide (Amipaque). Anti-convulsive premedication and clinical observance over a period of 24 h are necessary due to adverse reactions.
D000328:Adult; D002528:Cerebellar Neoplasms / Q000000981:diagnostic imaging; D002530:Cerebellopontine Angle / Q000000981:diagnostic imaging*; D002946:Cisterna Magna / Q000000981:diagnostic imaging*; D004244:Dizziness / Q000139:chemically induced; D004401:Dysarthria / Q000139:chemically induced; D004569:Electroencephalography; D004584:Electronystagmography; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007278:Injections, Spinal; D008297:Male; D008793:Metrizamide / Q000009:adverse effects*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010292:Paresthesia / Q000139:chemically induced; D011859:Radiography; D012640:Seizures / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D008793:Metrizamide
Nebenwirkungen bei der Metrizamid-Meatozisternographie.